Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Portola May Need Randomized Trial For AndexXa Approval. The Question Is When

Executive Summary

Randomized trial represents higher bar for US approval of reversal agents for novel anticoagulants than expected – and if needed prior to approval, could delay AndexXa launch for two or maybe even four years.

You may also be interested in...



User Fee Forecast For May: Approvals Could Sprout In Multiple Divisions

Aimovig, Andexxa, Lucemyra, and pegvaliase are among the almost 20 products with upcoming user fee goals at US FDA this month.

Bristol/Pfizer's Eliquis Better For Preventing Strokes And Bleeding In Large Real-World Trial

In Bristol/Pfizer's ARISTOPHANES real-world study, the rate of major bleeding with Eliquis was 46% lower than J&J/Bayer's Xarelto and 33% lower than Boehringer's Pradaxa.

Portola's Supplementary Approval Paves Way For Belated Bevyxxa Launch

Bevyxxa finally set to become the fifth new oral anticoagulant on the US market, but in a unique, niche indication of acute medical illness.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel